April 8 (Reuters) - Eli Lilly And Co LLY.N
* Eli Lilly And Company and Astrazeneca (LON:AZN) announce
continuation of pivotal clinical trial for people with early
Alzheimer's disease
* Eli Lilly And Company and astrazeneca announce
continuation of pivotal clinical trial for people with early
alzheimer's disease
* Amaranth, in development as potential treatment for early
alzheimer's disease, tp continue to phase 3 of phase 2/3
seamless trial
* Says Astrazeneca will receive a milestone payment from
lilly now that azd3293 has moved into phase 3 testing
* Says payment will result in Q2 charge of $100 million
(pre-tax) to Lilly's GAAP and Non-GAAP research and development
expense
* Says Lilly and Astrazeneca have also announced planned
initiation of a new phase 3 trial for AZD3293
* Says daybreak will begin enrolling participants in Q3 of
2016
Source text for Eikon: ID:nCNWjyRK8a
Further company coverage: LLY.N
(Bengaluru Newsroom; +1 646 223 8780) April 8 (Reuters) - Eli Lilly And Co LLY.N :
* Eli Lilly and Company (NYSE:LLY) and AstraZeneca announce
continuation of pivotal clinical trial for people with early
Alzheimer's disease
* AMARANTH, in development as potential treatment for early
alzheimer's disease, to continue to Phase 3 of Phase 2/3
seamless trial
* Says AstraZeneca will receive a milestone payment from
Lilly now that AZDd3293 has moved into Phase 3 testing
* Says payment will result in Q2 charge of $100 million
(pre-tax) to Lilly's GAAP and non-GAAP research and development
expense
* Says Lilly and AstraZeneca have also announced planned
initiation of a new Phase 3 trial for AZD3293
* Says DAYBREAK will begin enrolling participants in Q3 of
2016
Source text for Eikon: ID:nCNWjyRK8a
Further company coverage: LLY.N